SAGE Therapeutics

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SAGE Therapeutics poised for Zuranolone launch in 2023, overcoming challenges

SAGE Therapeutics showcased strong financial performance and promising developments with Zuranolone, positioning the drug favorably for potential launch in 2023.
While facing challenges such as enrollment issues and DEA scheduling impacts, the company is leveraging opportunities in commercialization strategies and post-marketing studies to enhance Zuranolone's market presence.
Overall, Zuranolone's rapid and durable effects, alignment with current treatment practices, and targeted commercialization approach present a compelling opportunity for SAGE Therapeutics in the mental health treatment landscape.
By addressing challenges effectively and capitalizing on opportunities, SAGE Therapeutics is poised to make a significant impact in advancing treatments for mood disorders and improving patient outcomes.

Sage Therapeutics reports strong Q1 performance and eyes market expansion

Sage Therapeutics had a strong Q1 2023, focusing on brain health medicines and preparing for zuranolone's launch.
The company's financial position is solid, with growth opportunities in pipeline programs and proactive payer engagements.
Challenges include regulatory uncertainties and competition, but Sage is well-positioned to capitalize on market demand.
Opportunities lie in expanding product indications, proactive agreements with payers, and learning from competitors for strategic advantage.

SAGE Therapeutics to Launch Zurzuvae for Postpartum Depression, Overcomes FDA Setback

SAGE Therapeutics is poised to launch Zurzuvae for postpartum depression, leveraging its financial strength and clinical success. While facing challenges in MDD, the company is strategically adapting to focus on PPD and enhance operational efficiency. Opportunities lie in collaborations, pricing strategies, and addressing the significant market need for PPD treatments.

SAGE Therapeutics advances women's health with ZURZUVAE approval

SAGE Therapeutics navigates financial challenges while advancing innovative treatments for women's health.
ZURZUVAE's approval and commercialization plans present opportunities in a significant market segment.
Strategic focus on engagement, access, and market positioning key to ZURZUVAE's success.
Pipeline advancements and collaboration efforts position SAGE for future growth and impact.

SAGE Therapeutics excels with ZURZUVAE launch, poised for continued growth

SAGE Therapeutics had a strong performance in 2023, driven by the successful launch of ZURZUVAE and positive early market reception.
While facing challenges in data tracking and market competition, the company's focus on innovation and patient access presents growth opportunities.
With a robust pipeline and strategic initiatives in place, SAGE is well-positioned to maintain momentum and drive further success in the brain health space.

SAGE Therapeutics reports strong Zurzuvae launch amidst Parkinson's study setback

SAGE Therapeutics is navigating challenges from the PRECEDENT study while capitalizing on Zurzuvae's successful launch for PPD.
The company's pipeline progress and commitment to addressing cognitive disorders in neurodegenerative diseases showcase a strong focus on brain health.
Collaborative efforts with Biogen, strong payer coverage, and positive market feedback position Zurzuvae as a frontline treatment for PPD.
Strategic initiatives to educate prescribers, expand market reach, and refine study designs present promising growth opportunities for SAGE.

SAGE Therapeutics faces setbacks but sees success with ZURZUVAE in Q2

SAGE Therapeutics navigates setbacks with SAGE-324 study closure but sees success with ZURZUVAE in PPD treatment. Strong financial foundation and commitment to brain health initiatives position the company for future growth.

SAGE Therapeutics focuses on Zurzuvae for PPD treatment success

SAGE Therapeutics prioritizes Zurzuvae for PPD, showing strong revenue growth and prescription uptake
Challenges include discontinuation of certain programs and mixed results in clinical studies
Opportunities lie in focusing resources, upcoming study results, and strategic program ownership
Overall, SAGE's reorganization reflects a strategic shift towards maximizing Zurzuvae's potential

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Sage Therapeutics (SAGE) Stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced participation in the first-ever Mental Health Action Day, on May 20, convened by MTV Entertainment Group and including more than 1,300 leading brands, nonprofits, government agencies and cultural leaders. Mental Health Action Day is an open-source movem

Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day

Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host the first Sage Science Spotlight webcast focused on an in-depth review of SAGE-718. Sage will provide details on its progress with SAGE-718, the company's lead neuropsychiatry product candidate being explored for the potential treatment of

Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth

Allakos Inc

Horizon Pharma

ImmunityBio

I-Mab

Mind Medicine MindMed

SpringWorks Therapeutics Inc

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on InvestorPlace.

7 of the Best Pharma Stocks to Buy Now

SAGE Therapeutics, Inc. (SAGE) CEO Barry Greene on Q1 2021 Results - Earnings Call Transcript

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 17.17% and -18.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the first quarter ended March 31, 2021. “Sage started 2021 with significant advances across our depression, neurology and neuropsychiatry franchises, and the progress we've made so far this year sets

Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Tuesday, May 4, 2021 at 8:00 a.m. ET to announce first quarter 2021 financial results and discuss recent business updates. The webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A

Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021

Biogen

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last year in November. SAGE-324, the second major molecule in the pact, cleared a Phase 2 trial for essential tremor (ET), a progressive disorder that causes involuntary muscle movement.

Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET). The study (n=67 full analysis set) achieved its primary endpoint of a statistically significant reduction from baseline compared to placebo in The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale Item 4 upper limb tremor score on Day 2

Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint

Gilead Sciences

Vertex Pharmaceuticals

Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday. He sees key products beating forecasts.

Biotech Stocks Could Use A Win — Will The First Quarter Offer That?

Lumber Liquidators

Perdoceo Education

When stocks are punished, it's not always for a good reason.

Knocked Down, These 3 Stocks May Rise Again

bluebird bio

Trillium Therapeutics

Though these stocks have dropped, upcoming news offers hope for them to rebound.

3 Top Biotech Stocks for Spring 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at the Stifel 3rd Annual CNS Day on Wednesday, March 31, 2021 at 8:00am ET. A live webcast of the fireside chat can be accessed on the investor page of Sage's website at investor.sagerx.com. A

Sage Therapeutics to Present at the Stifel 3rd Annual CNS Day

Bio-Rad Laboratories

Innoviva

Stocks to consider using Benjamin Graham's lost formula amid lingering pandemic fears

3 Health Care Stocks Trading Below Graham's Valuation

Can this brain health-focused biotech continue to rise, or will it fade -- again?

3 Reasons to Buy Sage Therapeutics, and 1 Reason to Pass

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open-label SHORELINE Study. This clinical study was designed to naturalistically follow patients with major depressive disorder (MDD) and evaluate the safety and tolerability of zuranolone 30 mg and 50 mg in adults for up to one year. For the primary endpoint of safety and tolerability, the data analyz

Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that Mike Cloonan, Sage's Chief Operating Officer, is leaving the company effective May 3, 2021 to pursue other opportunities. “Mike has made significant contributions to Sage over the past four years. We extend our thanks for his leadership and wish him noth

Sage Therapeutics Announces Departure of Chief Operating Officer

A Relative Strength Rating upgrade for Sage Therapeutics shows improving technical performance. The post Sage Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating appeared first on Investor's Business Daily.

Sage Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating

Expedia

Mattel

AT&T

Urban Outfitters

CME Group

Canadian Pacific Kansas City Limited

Global Blood Therapeutics

NetApp

With the trading day more than halfway over, the broad markets saw a huge pull back on Thursday.

AT&T, Expedia, Mattel, Urban Outfitters and More Thursday Afternoon Analyst Calls

Sage Therapeutics, Inc. (SAGE) CEO Barry Greene on Q4 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2020. “Although 2020 was a challenging year, Sage's commitment to rigorous science, innovation and disciplined execution resulted in significant pro

Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the following upcoming investor conferences: SVB Leerink Partners 10th Annual Global Healthcare Conference: on Thursday, February 25, 2021 at 8:00 am ET. Cowen & Co. 41st Annual Health Care Conference: on Mond

News for SAGE Therapeutics Stock (SAGE)